THERAPEUTIC CLASS

Lupus in crisis: as failures pile up, clinicians call for new tools

---

It was another bad year for drug development in lupus. The biggest setback for the field came in late August when AstraZeneca announced that its blockbuster hope anifrolumab, an antibody directed at a subunit of the type I interferon receptor, flunked the first of its two pivotal trials. Then came more bad news when UCB and Biogen reported toward the end of October that their phase 2b study of dapirolizumab pegol, a CD40 ligand–targeted PEGylated antigen-binding fragment, did not meet its primary endpoint either

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Allergy & Immune System

Specific Detail Info

NATURE BIOTECHNOLOGY VOLUME 37 NUMBER 1 JANUARY 2019

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment